Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system.
Mollenhauer B, Trautmann E, Otte B, Ng J, Spreer A, Lange P, Sixel-Döring F, Hakimi M, Vonsattel JP, Nussbaum R, Trenkwalder C, Schlossmacher MG. Mollenhauer B, et al. Among authors: otte b. J Neural Transm (Vienna). 2012 Jul;119(7):739-46. doi: 10.1007/s00702-012-0784-0. Epub 2012 Mar 18. J Neural Transm (Vienna). 2012. PMID: 22426833 Free PMC article.
The German CaRe high registry for familial hypercholesterolemia - Sex differences, treatment strategies, and target value attainment.
März W, Schmidt N, An Haack I, Dressel A, Grammer TB, Kleber ME, Baessler A, Beil FU, Gouni-Berthold I, Julius U, Kassner U, Katzmann JL, Klose G, König C, Koenig W, Koschker AC, Laufs U, Merkel M, Otte B, Parhofer KG, Hengstenberg W, Schunkert H, Stach-Jablonski K, Steinhagen-Thiessen E, Olivier CB, Hahmann H, Krzossok S, Vogt A, Müller-Wieland D, Schatz U. März W, et al. Among authors: otte b. Atheroscler Plus. 2023 Jun 12;53:6-15. doi: 10.1016/j.athplu.2023.06.001. eCollection 2023 Sep. Atheroscler Plus. 2023. PMID: 37434912 Free PMC article. Review.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
32 results